RYTM Rhythm Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RYTM

Price (delayed)

$88.265

Market cap

$6.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.13

Enterprise value

$5.99B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 23

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within ...

Highlights
RYTM's revenue has soared by 59% YoY and by 14% QoQ
The gross profit has soared by 58% YoY and by 14% from the previous quarter
The quick ratio has increased by 22% year-on-year but it has declined by 7% since the previous quarter
RYTM's net income is down by 20% year-on-year and by 3.1% since the previous quarter
Rhythm Pharmaceuticals's equity has decreased by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rhythmtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RYTM

RYTM stock price

How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
4.2%
1 week
-5.07%
1 month
3.14%
1 year
37.07%
YTD
-17.54%
QTD
1.49%

Financial performance

How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$217.17M
Gross profit
$194.16M
Operating income
-$197.37M
Net income
-$202.68M
Gross margin
89.4%
Net margin
-93.3%
RYTM's revenue has soared by 59% YoY and by 14% QoQ
The gross profit has soared by 58% YoY and by 14% from the previous quarter
The operating margin has grown by 28% YoY and by 10% from the previous quarter
The net margin has grown by 24% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does RYTM's price correlate with its fundamentals

Growth

What is Rhythm Pharmaceuticals's growth rate over time

Valuation

What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
49.04
P/S
27.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.58
The EPS has contracted by 11% YoY
Rhythm Pharmaceuticals's equity has decreased by 12% from the previous quarter
RYTM's P/B is 3.4% below its 5-year quarterly average of 48.7
RYTM's price to sales (P/S) is 88% lower than its 5-year quarterly average of 223.9 and 17% lower than its last 4 quarters average of 32.0
RYTM's revenue has soared by 59% YoY and by 14% QoQ

Efficiency

How efficient is Rhythm Pharmaceuticals business performance
The ROE has soared by 73% YoY and by 24% from the previous quarter
The ROS has grown by 22% YoY and by 9% from the previous quarter
Rhythm Pharmaceuticals's return on invested capital has increased by 14% YoY and by 7% QoQ

Dividends

What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RYTM.

Financial health

How did Rhythm Pharmaceuticals financials performed over time
The total assets is 116% more than the total liabilities
Rhythm Pharmaceuticals's current ratio has increased by 26% YoY but it has decreased by 5% from the previous quarter
The quick ratio has increased by 22% year-on-year but it has declined by 7% since the previous quarter
The debt is 97% smaller than the equity
The debt to equity has dropped by 86% year-on-year
Rhythm Pharmaceuticals's equity has decreased by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.